Image 2_Acute effects of exercise snacks on postprandial glucose and insulin metabolism in adults with obesity: a systematic review and meta-analysis.pdf by Yuanbo Chang (22654910)

“…Glucose tAUC and mean glucose showed non-significant downward trends. Mean insulin decreased (SMD = −0.54, 95% CI –0.97 to −0.10), albeit with high heterogeneity (I² = 76%). …”

Table 6_Acute effects of exercise snacks on postprandial glucose and insulin metabolism in adults with obesity: a systematic review and meta-analysis.docx by Yuanbo Chang (22654910)

“…Glucose tAUC and mean glucose showed non-significant downward trends. Mean insulin decreased (SMD = −0.54, 95% CI –0.97 to −0.10), albeit with high heterogeneity (I² = 76%). …”

Table 2_Acute effects of exercise snacks on postprandial glucose and insulin metabolism in adults with obesity: a systematic review and meta-analysis.docx by Yuanbo Chang (22654910)

“…Glucose tAUC and mean glucose showed non-significant downward trends. Mean insulin decreased (SMD = −0.54, 95% CI –0.97 to −0.10), albeit with high heterogeneity (I² = 76%). …”

Image 4_Acute effects of exercise snacks on postprandial glucose and insulin metabolism in adults with obesity: a systematic review and meta-analysis.pdf by Yuanbo Chang (22654910)

“…Glucose tAUC and mean glucose showed non-significant downward trends. Mean insulin decreased (SMD = −0.54, 95% CI –0.97 to −0.10), albeit with high heterogeneity (I² = 76%). …”

Table 5_Acute effects of exercise snacks on postprandial glucose and insulin metabolism in adults with obesity: a systematic review and meta-analysis.docx by Yuanbo Chang (22654910)

“…Glucose tAUC and mean glucose showed non-significant downward trends. Mean insulin decreased (SMD = −0.54, 95% CI –0.97 to −0.10), albeit with high heterogeneity (I² = 76%). …”

Image 1_Acute effects of exercise snacks on postprandial glucose and insulin metabolism in adults with obesity: a systematic review and meta-analysis.pdf by Yuanbo Chang (22654910)

“…Glucose tAUC and mean glucose showed non-significant downward trends. Mean insulin decreased (SMD = −0.54, 95% CI –0.97 to −0.10), albeit with high heterogeneity (I² = 76%). …”

Image 1_Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.tiff by M. Firoz Mian (10013314)

“…Notably, E2-induced increased B cell antibody responses conferred greater protection from HSV-2 challenge compared to placebo mice as evidenced by 2–3 logs decreased viral titers in the vaginal tract and 20% mice with genital pathology compared to 80% in placebo group, indicating better protection in E2-treated mice. …”

Image 2_Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.tiff by M. Firoz Mian (10013314)

“…Notably, E2-induced increased B cell antibody responses conferred greater protection from HSV-2 challenge compared to placebo mice as evidenced by 2–3 logs decreased viral titers in the vaginal tract and 20% mice with genital pathology compared to 80% in placebo group, indicating better protection in E2-treated mice. …”

Image 5_Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.tiff by M. Firoz Mian (10013314)

“…Notably, E2-induced increased B cell antibody responses conferred greater protection from HSV-2 challenge compared to placebo mice as evidenced by 2–3 logs decreased viral titers in the vaginal tract and 20% mice with genital pathology compared to 80% in placebo group, indicating better protection in E2-treated mice. …”

Image 3_Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.tiff by M. Firoz Mian (10013314)

“…Notably, E2-induced increased B cell antibody responses conferred greater protection from HSV-2 challenge compared to placebo mice as evidenced by 2–3 logs decreased viral titers in the vaginal tract and 20% mice with genital pathology compared to 80% in placebo group, indicating better protection in E2-treated mice. …”

Image 4_Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.tiff by M. Firoz Mian (10013314)

“…Notably, E2-induced increased B cell antibody responses conferred greater protection from HSV-2 challenge compared to placebo mice as evidenced by 2–3 logs decreased viral titers in the vaginal tract and 20% mice with genital pathology compared to 80% in placebo group, indicating better protection in E2-treated mice. …”

<b>Feeding Ecology of the Critically Endangered </b><b><i>Gobio insuyanus </i></b><b>(Gobionidae)</b> by Julian E. JOHNSON (20653776)

“…Dietary diversity was higher in the stream, potentially reflecting its greater habitat complexity, but decreased in both habitats in autumn, suggesting a seasonal decline in prey availability. …”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”